Clinical Trial Search

Primary: Patients With Treatment-emergent Adverse Events — 263 participants

Primary: Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2 — 0.75; 0.89…

Primary: Mean Change in 24-hour Pain Intensity Ratings Scale (NRS). — 0.48; 0.96 units on a scale

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 57; 5; 6; 0 participants

Primary: Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo — 39.6; 39.6; 24.5 Percentage of responders — p=<0.001

Primary: Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 — -0.022; 0.125; 0.116 Liters — p=<0.001

Primary: Change in QOL-B Respiratory Symptoms Score at Day 28 — 8.2; 3.2 units on a scale — p=0.011

Primary: Change in QOL-B Respiratory Symptoms Score at Day 28 — 7.4; 5.7 units on a scale — p=0.68

Primary: HIV Infection — 33; 35 participants

Primary: Seizure Frequency Over the 12-week Maintenance Period. — 7.88; 6.54; 6.00 Nº Standardized Seizures by 4 weeks — p=0.058

Primary: Change From Baseline in Endurance as Measured by the 6-minute Walk Test — 211.9; 205.7; 203.9; 225.4 meters — p=0.0174

Primary: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) — 11.8; 11.3 percentage of participants — p=0.315

Primary: Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT. — 0.76; 0.86; 0.86; 0.47 Proportion of participants — p=0.023

Primary: The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups…

Primary: Visual Analog Scale (VAS) Pain Score (Per Protocol) — 30.389; 28.917 mm on a 100 mm VAS scale — p=0.696